Fingerprint
Dive into the research topics of 'A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Monika Jermann, Rolf A Stahel, Marc Salzberg, Thomas Cerny, Markus Joerger, Silke Gillessen, Rudolf Morant, Fritz Egli, Kaspar Rhyner, Jean A Bauer, Miklos Pless
Research output: Contribution to journal › Article › peer-review